

SUBCOMMITTEE RECOMMENDATION

HB 4005

Relating to the price of prescription drugs

HB 4005 establishes the Prescription Drug Price Transparency Act, requiring manufacturers of prescription drugs sold in Oregon to report specified information to the Department of Consumer and Business Services. The bill also requires insurers to include specified information regarding reimbursement of certain drugs along with current filing of health insurance rates. In addition, the bill creates the Task Force on the Fair Pricing of Prescription Drugs charged with developing a strategy to create transparency for drug prices across the supply chain, including pharmacy benefit managers, distributors, as well as wholesale and retail pharmacies.

DCBS projects the cost of complying with the provisions of this bill to be \$425,022 Other Funds, 3 positions, 1.50 FTE for the 2017-19 biennium; and \$577,120 Other Funds, 3 positions, 3 FTE for the 2019-21 biennium. Funding for this program will be derived from fees to be paid to DCBS by manufacturers. Such fees will be set via rulemaking and are yet to be determined.

The Transportation and Economic Development Subcommittee recommends HB 4005 be amended by the –A24 amendment and be reported out do pass, as amended.